Showing posts with label Neuropathic. Show all posts
Showing posts with label Neuropathic. Show all posts

Friday, August 11, 2017

Combining Drugs For Neuropathic Disease Treatment Why Not


Today's post from sciencedaily.com looks at a new treatment for fibromyalgia, which is a chronic and mysterious disease recently found to be linked to neuropathy by the fact that it is stimulated by the central nervous system (brain and spinal cord). It suggests that a combination of pregabalin (Lyrica) and duloxetine (Cymbalta) works very well at reducing the symptoms. The direct link to neuropathy is obvious as both drugs are used singularly to treat neuropathy symptoms. It has also been suggested in the past that combination therapies are the best options for severe neuropathic symptoms but many doctors are reluctant to go down that path because of side effects. The side effects should not be underestimated (especially pregabalin (Lyrica) which has such a bad name yet is still widely prescribed for many neuropathies but the idea of combining treatments is not a bad one and one worthy of consideration in discussion with your doctor or neurologist. Combinations excluding Lyrica may be best, to avoid unpleasant side-effects but surely other options can be considered - there are enough drug treatments to choose from and as they rarely work on their own, a combination which will block pain bearing signals in the sodium channels seems like a logical step forward.

Fibromyalgia: Doubling up to fight pain
Combining two drugs used to treat fibromyalgia safely improves patient outcomes, according to researcher 
Date:July 13, 2016 Source:Queen's University

Queen's University researcher Ian Gilron has uncovered a more effective way of treating fibromyalgia, a medical condition characterized by chronic widespread pain typically accompanied by fatigue, as well as sleep, mood and memory problems.

The results of the trial suggest that combining pregabalin, an anti-seizure drug, with duloxetine, an antidepressant, can safely improve outcomes in fibromyalgia, including not only pain relief, but also physical function and overall quality of life. Until now, these drugs have been proven, individually, to treat fibromyalgia pain.

"Previous evidence supports added benefits with some drug combinations in fibromyalgia," says, Dr. Gilron (Anesthesiology, Biomedical Sciences). "We are very excited to present the first evidence demonstrating superiority of a duloxetine-pregabalin combination over either drug alone."

Fibromyalgia was initially thought to be a musculoskeletal disorder. Research now suggests it's a disorder of the central nervous system -- the brain and spinal cord. Researchers believe that fibromyalgia amplifies painful sensations by affecting the level and activity of brain chemicals responsible for processing pain signals.

"The condition affects about 1.5 to 5 per cent of Canadians -- more than twice as many women as men. It can have a devastating on the lives of patients and their families," explains Dr. Gilron. "Current treatments for fibromyalgia are either ineffective or intolerable for many patients."

This study is the latest in a series of clinical trials -- funded by the Canadian Institutes of Health Research (CIHR) -- that Dr. Gilron and his colleagues have conducted on combination therapies for chronic pain conditions. By identifying and studying promising drug combinations, their research is showing how physicians can make the best use of current treatments available to patients.

"The value of such combination approaches is they typically involve drugs that have been extensively studied and are well known to health-care providers," says Dr. Gilron.

This new research was published in the journal Pain.

Dr. Gilron and his research team at Queen's are members of the SPOR Network on Chronic Pain. The national network, funded under Canada's Strategy for Patient-Oriented Research, directs new research, trains researchers and clinicians, increases access to care for chronic pain sufferers, and speeds up the translation of the most recent research into practice.



Story Source:

The above post is reprinted from materials provided by Queen's University. The original item was written by Anne Craig. Note: Materials may be edited for content and length.

Journal Reference:
Ian Gilron, Luis E. Chaparro, Dongsheng Tu, Ronald R. Holden, Roumen Milev, Tanveer Towheed, Deborah DuMerton-Shore, Sarah Walker. Combination of pregabalin with duloxetine for fibromyalgia. PAIN, 2016; 157 (7): 1532 DOI: 10.1097/j.pain.0000000000000558


https://www.sciencedaily.com/releases/2016/07/160713143152.htm

Thursday, August 10, 2017

Diagnosis Diffculties With Neuropathic Pain


Today's post from articlesnatch.com (see link below) is another article discussing testing procedures and looks at how difficult the whole testing and diagnosis of various forms of neuropathy can be and how a lack of clear results during the testing process can lead to mis-diagnoses.

Diagnostic And Therapeutic Issues Of Neuropathic Pain
By: Sam Edwards

The use of laboratory studies and imaging studies in the diagnosis of neuropathic pain present clinical challenges and, although medications remain the mainstay of therapy, it is frequently necessary to try multiple different medications and modalities for adequate treatment.

There are two types of pain: nociceptive and neuropathic. The former is of a mechanical nature and relates to nerve pain through direct nerve irritation, such as an arthritic joint. The latter implies a specific injury or insult to nerves causing pain and discomfort. Based on my clinical observations in treating patients with neuropathic pain for almost 20 years, it is my belief that neuropathic pain and, in particular, radicular pain has been under-diagnosed and under-treated for a variety of reasons. Partly its our reliance on electrodiagnostic testing in making the diagnosis of radicular pain and the difficulty in obtaining an accurate history from the patient, and an absence of other diagnostic testing to make this diagnosis. Also, health care professionals often overlook the neuropathic component of pain and focus on other causes of chronic pain. Further, the difficulty in the treatment of neuropathic pain presents a clinical challenge.

Neuropathic pain includes, but is not limited to diabetic neuropathy, all peripheral neuropathies, radiculopathy, complex regional pain syndrome, sympathetically mediated pain, fibromyalgia, and interstitial cystitis. A variety of medical conditions that cause peripheral neuropathy include inherited diseases, alcoholism, nutritional vitamin deficiencies, cancers, autoimmune reactions, medications, kidney and thyroid disease and infections such as Lyme disease, shingles or AIDS. Peripheral neuropathy of idiopathic etiology, diabetic peripheral neuropathy, radiculopathy and mono-neuropathies make up the majority of all the causes of neuropathic pain.


Diagnostic Issues
Although the diagnosis of a specific type of neuropathic pain can be complicated, distinguishing between neuropathic pain and nociceptive pain is not as complicated. It is important to distinguish pain patterns in making the diagnosis of neuropathic pain. Practitioners should evaluate the patients as to whether the pain involves an extremity and, if so, is it radiating from the spine or is it a separate pain of a joint or a separate part of the extremity.
Pain location is important and the patient needs to elaborate specifically where the pain occurs. It is helpful to use a pain diagram to show where their pain is located. The practitioner should then go over the diagram with the patient and complete an examination and have the patient show them physically on their body where the pain occurs. If the pain involves an extremity, is it sock-like pain or is it linear in fashion? Are there neurological changes on examination and does the patient have other neurological symptoms or complaints such as numb-ness or tingling?
For the purpose of this article, Noxicare Natural Pain Relief examined 30 patients in my clinic with chronic back pain and confirmed compressive pathology in patients who also had extremity pain. Of those 30 patients, only two were able to adequately describe a radicular symptomatology that could be considered as anatomically accurate. Less than half the patients had EMG studies and, of those, about two thirds were reported as negative. In our practice, we have found that the treatment of radicular pain has frequently been denied specifically based on these two issues: that there is a lack of a clear dermatomal pain pattern, and that there is a normal EMG report.

http://www.articlesnatch.com/Article/Diagnostic-And-Therapeutic-Issues-Of-Neuropathic-Pain-/3794002



Thursday, August 3, 2017

Nerve Cell Transplantation Study For Neuropathic Pain


Today's post from allvoices.com (see link below) reveals a little bit more information about the research into the transplantation of nerve cells to treat neuropathic pain. It's a complex subject so every new explanation of how it works will add to our understanding. It's clearly still a long way away from being successfully used on humans but the signs are good.


New study finds treatment for neuropathic pain
May 27th, 2012 by Sarah1
The neuropathic pain that results from damage to neurons was again studied by scientists recently. They experimented the transplantation of neurons to replace the damaged ones. The experiment involved transplanting immature neurons in mice. The immature neurons grew into full-nerve cells but not all of the those survived. However, it was proved that they can actually grow and function as complete cells.
"Now we are working toward the possibility of potential treatments that might eliminate the source of neuropathic pain, and that may be much more effective than drugs that aim only to treat symptomatically the pain that results from chronic, painful conditions," the senior author of the study, Allan Basbaum PhD, who is also the chair of the Department of Anatomy at UCSF, states in the study report, as reported on sciencedaily.com. The previous post here on the blog can be seen by clicking here.

Neuropathic pain is very difficult to treat, as even strong painkillers do not act on it. The study aimed at finding a way to treat the pain and the related diseases by replacing the lost nerve cells. The co-author of the study, Arnold Kriegstein, commented on the research, saying that he feels it is a starting point for further study. "This research is at a very early stage, and we're a long way from thinking about it in human trials, but we do have a method of making cells that are like these inhibitory neurons, starting with human embryonic stem cells," Kriegstein said in his remarks, as reported on sciencedaily.com.

The study suggests that transplantation of nerve cells would have a direct effect on the pain, something which is not achievable by medication. The advancement in the research can potentially lead to a conclusive treatment for humans, as the results of this experiment are very encouraging. "Unlike drugs, the transplanted cells can have very focused effects, depending on where they are transplanted," Kriegstein said about the new finding.

There might be various causes of the pain and the scientists are working on determining the specific causes that are treatable by this newly proposed therapy. They are hopeful that they would be successful in finding the cure through this method. The study has opened a new window for the treatment of neuropathic pain, which is usually considered untreatable.

sarah1 is based in California, California, United States of America, and is a Reporter for Allvoices.    

http://www.allvoices.com/contributed-news/12256335-study-conducted-to-find-treatment-for-chronic-pain      

Tuesday, July 11, 2017

Neuropathic Pain


Today's post from geenabhud.wordpress.com (see link below) has no visible original author and doesn't refer back to the original source but nevertheless, contains some very useful information for those wondering how neuropathic pain works and why it feels the way it does. It also refers to several verifiable scientific studies and is clearly informative and not opinion-based. Having checked through the article, the information is verifiable on countless other sites and working on the principle that neuropathy patients deserve to read all available information and from many different angles, this post is worth a read.

 

Treatment of Painful Peripheral Neuropathies
footpadpatch: November 6, 2012

INTRODUCTION

Peripheral neuropathy is a common problem and for some patients, pain is a disabling component of the neuropathy. The first goal in evaluating patients with painful peripheral neuropathies is to identify the cause, with the hope of identifying treatment to reverse nerve damage. There are a large number of disorders that may be associated with a painful peripheral neuropathy. (Table 1) When neuropathic pain is present, it is appropriate to treat this concurrently, during the evaluation, as well as during the treatment of the neuropathy, if identified is in process. For some types of neuropathy, there are no available treatments for the underlying disorder, and therapy for neuropathic pain, if present may be the only treatment available.

Pain can be classified broadly as two types. Nociceptive pain is protective and is a normal response to tissue injury, serving to warn of the presence of injury. There is also sensitization of peripheral nociceptors and central nervous system changes, which protect the damaged area by avoiding contact.

Neuropathic pain is a pathologic or maladaptive pain, which results from damage to the nervous system, producing pain in the absence of stimulation of nociceptors or inappropriate response to stimulation of nociceptors. Nociceptive and neuropathic pain are not synonymous with acute and chronic pain. For instance, rheumatoid arthritis is a chronic pain, which is nociceptive pain. A herniated disc can cause acute sciatic pain, which is neuropathic.

Patients with neuropathic pain typically describe burning, lancinating, stabbing, cramping, aching and sometimes vice-like pain. It can be paroxysmal or constant. On examination hyperalgesia, allodynia or hyperpathia are sometimes elicited.

The normal pathways involved in the transmission of pain begin with stimulation of nociceptors including those that respond to chemical irritant stimuli such as VR1, DRASIC, P2X3 and noxious heat stimuli such as VR1 and VRL1. Signals resulting from intense mechanical and thermal stimulate A delta fiber nociceptors and intense mechanical ,thermal and chemical stimuli stimulate polymodal C nociceptors. Afferent fibers synapse in Rexed’s lamina I, II and V in the spinal cord, which is the first level of modulation. Opiate receptors and interneurons are present at the dorsal horn. There are are also descending inputs from the hypothalamus, periaqueductal gray. Opiods, norepineprhine and serotonin have modulatory effects on pain transmission.

MECHANISMS OF NEUROPATHIC PAIN
Why certain neuropathies cause pain is unknown, but there has been increasing knowledge about the mechanism of pain. The gate theory of pain proposed that the substantia gelatinosa acted as a gate allowing pain transmission to proceed and that the inhibitory affect of the substantia gelatinosa is increased by large diameter fibers. Central descending influence was also postulated. [Melzack and Wall 1965]Though specifics of this theory have been shown to be incorrect, the basic premise of central modification of pain perception at the dorsal horn and other parts of the central nervous system is still held. Dyck et al [Dyck et al. 1976], noted that neuropathic pain was related to the rate and kind of nerve fiber degeneration. It is not related simply to the ratio of remaining large and small nerve fibers. Brown et al noted that unmyelinated and small myelinated fibers were most prominently involved and unmyelinated nerve fiber sprouting was evident in painful diabetic neuropathy. [Brown et al. 1976]

Animal models of pain have added to the understanding of neuropathic pain. There are 4 commonly used animal models, which include the chronic constrictive injury (CCI) model, the partial nerve transection, spinal nerve transection model and the spared nerve model. [Kim and Chung 1992;Seltzer et al. 1990;Bennett and Xie 1988;Decosterd and Woolf 2000]The chronic constrictive injury model is produced by a loosely constrictive ligature around the sciatic nerve. [Bennett and Xie1988] Almost all of A-β fibers die, as do the majority of Aδ fibers. A large percentage of C fibers persist.

The partial nerve transection model involves tightly ligating and transecting 1/3 to ½ of of the rat sciatic nerve. The spinal nerve transection model involves tight ligation and transection of the L5 and L6 nerve roots. This affects 50% of the sural and saphenous nerve fibers. The spared nerve model involves a lesion of 2 of the 3 terminal branches of the sciatic nerve (tibial and peroneal) intact, leaving the sural nerve intact. [Decosterd and Woolf2000]There is partial deafferentation but not differential involvement of nerve fibers, in these three models.

Heat hyperalgesia, mechano-hyperalgesia, mechano-allodynia and cold-allodynia may be observed and behavioral changes consistent with spontaneous pain such as limping and guarding the hind paw are seen. Both peripheral and central mechanisms have been observed in animal models.

After nerve injury there are spontaneous discharges of nerve fibers, neuromas and dorsal root ganglion. This has been seen in traumatic nerve injury models , as well as models of peripheral neuropathy from diabetes and heavy metal intoxication. Increased expression of sodium channels are seen in neuroma’s in humans and animal models. The density of sodium channel expression correlates with the degree of pain. [England et al. 1996] Changes in sodium channel expression are seen and may contribute to nerve excitability and spontaneous pain. [Waxman et al. 1999;Craner MJ et al. 2002].

These spontaneous discharges by themselves can cause pain, but they also have additional affects. C fiber afferents trigger cell death of neurons in the dorsal horn, where inhibitory interneurons are concentrated, possibly through an excitotoxic mechanism. This may result in increased pain transmission.. ([Sugimoto et al. 1989;Sugimoto et al. 1990;Laird and Bennett 1992] C fiber afferents release glutamate and synapse on 2nd order neurons and have excitatory affects. Glutamate synapses at AMPA receptors which depolarizes the membrane. This depolarization releases the inhibition of the NMDA receptor by the magnesium ions and there is an influx of calcium. Second order neurons are gradually depolarized and responses are amplified and this changes the response of neurons to subsequent input.

Two processes that are distinct occur at the dorsal horn which are designated “windup” and “central sensitization.” Windup up results from repetitive C fiber firing at low frequencies that result in a progressive buildup of the amplitude of the response of the dorsal horn neuron, only during the repetitive train. Central sensitization is an abnormal sensitivity with a spread of hypersensitivity to uninjured sites and pain resulting from stimulation of low threshold A mechanoreceptors. Central sensitization follows a brief high frequency input and the increased response to subsequent inputs is prolonged. Both can be blocked by NMDA receptor antagonists. Central sensitization can result from windup. This is a result of the calcium influx through the NMDA receptor following depolarization of the dorsal horn membrane. The intracellular calcium activated a number of kinases of which protein kinase C (PKC) is likely important. PKC enhances the NMDA receptor , which results in subsequent glutamate binding of the NMDA receptor generating an inward current. Though windup can result in central sensitization it is not necessary for central sensitization to occur. [Woolf and Salter 2000;Woolf 1996]

Similar observations had previously been noted by Denny-Brown who described an enlarged and hypersensitive dermatomal region in primates when severing the surrounding nerve roots distal to the dorsal root ganglion compared with severing proximal to the DRG. This suggested plasticity of the dorsal horn neurons secondary to input from the DRG. [Kirk and Denny-Brown 1970;Kirk and Denny-Brown1970;Denny-Brown et al. 1973]

Nerve injury also results in sprouting of myelinated fibers into lamina II of the dorsal horn, which under normal circumstances receives only C fiber input. [Mannion et al. 1996]This may result in allodynia.

There is a genetic influence on the experience of neuropathic pain though it is poorly delineated. There are variations on the expression of pain behaviors seen in different strains of animals. [Devor and Raber 1990] A recent study noted that 56% of patients with painful diabetic neuropathy had a relative with painful diabetic neuropathy suggesting a genetic component.[Galer et al. 2000]

The relative importance of these various mechanisms is not clearly known, however there is potentially multiple sites for intervention in treating painful neuropathies.

Medications
Tricyclic anti-depressants have been beneficial in controlled studies of neuropathic pain. [Max 1995]They block the reuptake of norepinephrine and serotonin and are thought to modulate descending inhibitory pathways. There benefit with neuropathic pain is independent of their effect on depression. [Max et al. 1987] Patients who are not depressed can respond and lower doses than are used to treat depression are effective to treat neuropathic pain. Tricyclic anti-depressants can block voltage dependent sodium channels and this may contribute to their efficacy to treat neuropathic pain. [Brau et al. 2001] They are typically started at a dose of 10-25 mg at night and titrated as tolerated up to a dose of 150 mg if necessary. Side effects include dry mouth, cardiac arrhythmias, urinary retention and sexual dysfunction. Venlafaxine has fewer side effects and has also been reported to benefit neuropathy pain. [Ansari 2000]

The selective serotinin reuptake inhibitors (SSRI) have been less effective for treatment of neuropathic pain. Fluoxetine was not effective in clinical trials. [Max et al. 1992]Paroxetine and Citalopram been reported to be effective. [Sindrup et al. 1992;Sindrup et al. 1990]

Anticonvulsants have also been studied in neuropathic pain. Both phenytoin (Dilantin) and carbamezapine (Tegretol) have been beneficial in trials of diabetic neuropathy. [Chadda VS 1978;Rull et al. 1969]They act as sodium channel blockers. Both medications have frequent side effects that are well known.

Gapapentin (Neurontin), binding site alpha delta Ca channel. It is though to act at a spinal site of action. [Xiao and Bennett 1996] Controlled studies in diabetic neuropathy, post-herpetic neuralgia and other neuropathic pain states. [Backonja et al. 1998] Starting doses are usually100mg tid or 300mg qhs. Unless the drug is not tolerated or a dose of 600 mg tid has been tried it should not be considered a treatment failure. Often higher doses provide more benefit. Side effects include drowsiness, fogginess, leg edema. Gabapentin is cleared by the kidneys and there are not significant drug interactions. The dosing should be adjusted in renal insufficiency and failure.

Lamotrigine (Lamictal) is a sodium channel blocker, which also inhibits glutamate release. It has reduced cold allodynia in the CCI model. [Hunter et al. 1997]Lamotrigine is effective in controlled studies in diabetic, HIV associated painful neuropathy, post-herpetic neuralgia, and trigeminal neuralgia.[Simpson et al. 2000;Eisenberg et al. 2001]. I’ve found lamotrigine to cause less drowsiness or dizziness than most other medications used for neuropathic pain and though these symptoms have been seen during epilepsy trials, they were not seen more commonly than placebo in 2 recent trials of neuropathy pain. Rash is a side effect and a Stevens Johnson syndrome may occur. This is less frequent when the medication is titrated slowly. The rash is less common with a slow titration. The following titration schedule has been used for neuropathic pain: 25mg qd for 2 weeks, 25 mg bid for the next 2 weeks, 50 mg bid for the next 2 weeks, 100mg bid for 2 weeks. If the patient is also taking valproate which inhibits the metabolism of lamotrigine, a dose of 25 mg qod is recommended as an initial dose.

Oxcarbazepine (Trileptal) is similar in structure to carbamezapine, but lacks the 10,11 epoxide, which is thought to be responsible for better tolerability. Autoinduction does not occur and rash and drug interactions are less frequent than with carbamezapine. Hyponatremia does occur. [Zakrzewska and Patsalos 1989]

Double blind placebo controlled studies of mexilitine have been negative, however subgroups with stabbing and burning pain had benefit. Another study noted benefit in night time pain with the 675 mg dose, but not the lower doses of 450 mg or 225 mg.

Topiramate (Topamax) showed benefit in animal models and preliminary studies and anecdotal reports of diabetic neuropathy and neuropathic pain. [Edwards et al. 2000;Potter and Edwards 1998]Though the results have not been published Johnson & Johnson announced that the results of clinical trials in diabetic neuropathy pain were not positive (Reuter 9/18/2001).

Dextromorthorphan is a low affinity NMDA antigonist. It has been beneficial in animal studies and painful neuropathies. Side effects are frequent and it is poorly tolerated. [Nelson et al. 1997] Dextromethorphan in combination with other medications as well as more selective NMDA receptor antagonists that may have less side effects are being pursued.[Boyce et al. 1999]

Clonidine an alpha-2 agonist, as a transdermal patch was successfully used in a subset of patients with painful diabetic neuropathy using an enrolled enrichment design. Tizanidine, also an alpha-2 agonist, reduces thermal hyperalgesia in the CCI rat model and has been successful in open label studies in neuropathic pain.[Hord et al. 2001;Semenchuk and Sherman 2000b]

Tramodol (Ultram) has been effective in studies of painful diabetic neuropathy.[Harati et al. 1998] Side effects include nausea, headache, constipation, somnolence and seizures. Lidoderm is beneficial for post-herpetic neuralgia. The dose of 1-3 patches for 12 hours, with 12 hours off the patch. It has been beneficial in other forms of neuropathic pain. [Devers and Galer 2000]

Based on small preliminary and anecdotal series, as well as animal data, other medications including zonisamide and levetiracetam may be beneficial. [Backonja 2002;Semenchuk and Sherman 2000a;Hord et al2001]

HIV painful neuropathy is a particularly difficult syndrome to treat. Controlled studies of amitriptyline, mexilitine, and acupuncture have been negative. [Shlay et al. 1998;Kieburtz et al. 1998]Gabapentin has been reported to be successful, though requiring higher doses. [Newshan 1998] Phenytoin and carbamezapine as P450 inducers should be avoided as they can induce the metabolism of the protease inhibitors and make them ineffective. [Romanelli et al. 2000]Lamotrigine has been successful in blinded placebo controlled studies. Two consecutive studies however provided conflicting data with the first suggesting that there was no benefit above placebo in patients taking neurotoxic dideoxynucleotide anti-retrovirals compared with those patient not taking neurotoxic antiretrovirals and the second study showed the opposite. [Simpson et al. 2002;Simpson et al2000]

Since several different mechanisms are involved in neuropathic pain, treatment directed against the mechanism of pain would be desirable and has been proposed. Unequivocally identifying mechanisms at work to date has been difficult in patients. For instance the symptom of allodynia may occur from peripheral sensitization or central sensitization. [Woolf et al. 1998] It is a commonly held belief that tricyclic anti-depressants are more effective against burning pain and anti-convulsants are more effective against paroxysmal stabbing pain. In clinical trials however this has not been demonstrated.. Selective affects in animal models have been demonstrated. For example dextrorphan reduces heat hyperalgesia, but has no effect on mechanical allodynia in the CCI model. [Tal and Bennett 1994] How this correlates to treatment of people with neuropathic pain is still evolving. In the future cocktails targeting different mechanisms at work in patients with peripheral neuropathies may be possible.


http://geenabhud.wordpress.com/2012/11/06/d461/

Monday, July 3, 2017

Pressure Stocking Detects Neuropathic Injury Points


Today's post from diabetes.co.uk (see link below) covers something we've mentioned earlier on the blog and that is a new commercial stocking/sock which will sense when undue pressure is being put on certain areas of the feet and will hopefully prevent pressure sores and worse for people with severe numbness in their feet. it looks as though it's going to be costly, maybe too costly for the individual neuropathy sufferer but hopefully it will be introduced into insurance coverage packages and thus be available for those who need them. The question is, do you need something like this? Most neuropathy sufferers don't have total loss of feeling in their feet - having numbness in the pads of the feet but generally retaining some sort of feeling to detect the ground under their feet. This will be useful for those unfortunate people who have lost all feeling and are therefore at serious risk of undetected injury. An interesting development - worth a read.

New pressure-monitoring device could prevent neuropathy-related injuries
Kurt Wood Thu, 14 May 2015


Researchers from Germany have developed a pressure-monitoring stocking that could prevent foot wounds in people with diabetic neuropathy.

The device, which was developed by researchers at the Fraunhofer Institute for Silicate Research ISC in Würzburg, uses integrated sensors to send warnings when pressure on the foot is too high, essentially performing the job of the nerves in the feet.
Neuropathy and foot pressure Diabetic neuropathy is one of the most common diabetic complications. Over time, prolonged exposure to high blood glucose levels damages the nerves in the feet. Diabetic neuropathy is the leading cause of amputation in the UK.

When people develop diabetic neuropathy, they lose the feeling in their feet. This can have a number of damaging effects. One such effect is the inability to notice the amount of pressure being placed on the feet. People without diabetic neuropathy have functioning nerve pathways that automatically redistribute when the person is standing up for a long time.

Over time, excessive weight placed on the feet can lead to the development of pressure sores, which can in turn lead to open wounds or damaged foot tissue.
How does the pressure stocking work? The stocking features 40 dielectric elastomer sensors that measures pressure distribution. The sensors are made from a special silicone film. When pressure builds on the foot - usually because of standing in the same place for a while - the sensors transmit a signal to a wireless electronics unit.

The stocking will cost around £180. 


What makes the pressure stocking different? There are several products available to balance out pressure on the foot for people with diabetes, but this one is different, according to Dr. Bernhard Brunner, of the Fraunhofer institute:

"Existing systems on the market measure the pressure distribution only on the bottom of the foot using shoe inserts. Our sensors are attached to the stocking's sole, at the hell, the top of the foot and the ankle, so they can take readings in three dimensions. This is a totally new approach."
Moving forward The device is brand new, and some creases still to be ironed out. Dr. Brunner explained the challenges that face the team going forward:

"With the current prototype, the electronics are attached to the end of the stocking. We're planning to relocate them to a small, button-sized housing that can be detached with a hook-and-loop fastening strip. There's no way around this until a reliable method for cleaning the electronics is developed."

The sensors have to be washable, too. "The first washability tests are in planning, but cleaning using disinfectant is no problem."

The researchers have filed a patent application for the stockings. From May 19 to May 20, the team will be presenting a prototype of the stockings at the SENSOR+TEST 2015 Measurement Fair in Nuremberg.


http://www.diabetes.co.uk/News/2015/May/new-pressure-monitoring-device-could-prevent-neuropathy-related-injuries-97065315.html

Thursday, June 29, 2017

What Will Help Tracking Genetic Reasons For Neuropathic Pain


Today's post from sciencedaily.com (see link below) looks at a problem scientists have faced when confronted with the question: is neuropathy genetic? The problem is the lack of a standard approach to assessing its clinical characteristics (otherwise known as a 'phenotype'). However, recently there seems to have been a breakthrough and they have developed criteria which categorise what neuropathy 'looks like' genetically and clinically. It's thought that this will help in understanding how neuropathic pain develops, leading to new approaches to treatment and prevention. Hopefully this is the case and we can look forward to effective treatments reaching our doctors' prescription pads sooner rather than later.
 
Standard phenotypes will aid in genetic research on neuropathic pain 
Date:October 26, 2015 Source:Wolters Kluwer HealthSummary:

Research on the genetic factors contributing to neuropathic pain has been hindered by the lack of a standard approach to assessing its clinical characteristics or "phenotype." Now, a report from an expert panel published in the journal PAIN® presents a consensus approach to assessing the phenotype of neuropathic pain. The journal is the official publication of the Wolters Kluwer.

Standardized "entry level" criteria for defining the phenotype of neuropathic pain were developed by an international panel of experts assembled by the IASP's Special Interest Group on Neuropathic Pain (NeuPSIG). Along with other recommendations for research reporting, the consensus criteria will achieve "greater consistency and transparency in studies of neuropathic pain in adult humans." Dr. Blair H. Smith of the University of Dundee, Scotland, is lead author of the expert panel report.

Setting Standard Criteria to Define Neuropathic Pain Phenotypes


Neuropathic pain is a common and complex pain condition caused by damage or diseases of the sensory nerves. Patients may experience shooting or burning pain, numbness, or exaggerated pain responses. Neuropathic pain can be caused by diabetes, trauma, shingles, and a wide range of other conditions.

Information on genetic factors may help in understanding how neuropathic pain develops, leading to new approaches to treatment and prevention. But so far, genetic studies have produced inconsistent results that are difficult to confirm. This is partly because of differing approaches used to identify and classify the clinical expression and characteristics of this condition, which can vary widely.

To address this problem, the expert panel "aimed to provide guidelines on collecting and reporting phenotypes" of neuropathic pain. After a thorough review of previous research evidence, panel members followed a formal consensus process to develop a set of "entry level" phenotype data to identify and classify patients with neuropathic pain, as well as appropriate comparison (control) groups.

Following this process, the NeuPSIG panel identified three basic elements:
Pain with neuropathic characteristics (described as "hot/burning" or "evoked by light touch") or assessed using a validated screening tool
Pain distributed or located in a pattern that is anatomically consistent with underlying nerve damage or disease (in other words, the pain is consistent with the anatomy of the affected sensory nerves)
Additional information on pain history and characteristics and other factors relevant to the disease or group of patients being studied

Reflecting the challenges of diagnosing neuropathic pain, the report emphasizes that these "entry level" criteria identify only "possible" cases of neuropathic pain. Depending on the situation, additional criteria could be used to identify "probable" or "definite" cases, or additional sensory or psychological assessments could be conducted to further characterize the phenotype.

The new criteria are published as IASP concludes its 2014-2015 Global Year Against Neuropathic Pain campaign. By improving awareness among patients and health-care providers, IASP hopes to improve recognition and management of this disabling and difficult-to-treat condition.

The consensus phenotype criteria will be an important step toward a more productive approach to studying the genetic factors contributing to neuropathic pain, the NeuPSIG panel members believe. They conclude, "These improvements will facilitate advancements in the field by enabling collaboration between research groups, replication of discoveries of contributing genetic variants, meta-analyses, and translation from the laboratory to the general population, and back again."

Story Source:


The above post is reprinted from materials provided by Wolters Kluwer Health. Note: Materials may be edited for content and length.

Journal Reference:

Oliver van Hecke, Peter R. Kamerman, Nadine Attal, Ralf Baron, Gyda Bjornsdottir, David L.H. Bennett, Michael I. Bennett, Didier Bouhassira, Luda Diatchenko, Roy Freeman, Rainer Freynhagen, Maija Haanpää, Troels S. Jensen, Srinivasa N. Raja, Andrew S.C. Rice, Zeʼev Seltzer, Thorgeir E. Thorgeirsson, David Yarnitsky, Blair H. Smith. Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies. PAIN, 2015; 156 (11): 2337 DOI: 10.1097/j.pain.0000000000000335


http://www.sciencedaily.com/releases/2015/10/151026132144.htm

Friday, June 23, 2017

Is Cymbalta Duloxetine The Answer For Neuropathic Pain


Today's post from battlediabetes.com (see link below) is a two pronged one for neuropathy sufferers. It talks mainly about taking cymbalta (duloxetine) to control neuropathy symptoms and comes up with some negative conclusions (which won't be a surprise for many on the drug). It also highlights diabetes and shows a video of a young boy's daily life with that disease. Whatever the cause of your neuropathy, if it is not diabetes, then for general knowledge alone the video is worth watching, if only to understand how difficult life with diabetes can be.

How Can Cymbalta Fight Diabetic Neuropathy Nerve Pain?

Cymbalta is an SSRI antidepressant which was being prescribed off label to diabetes patients who were suffering from diabetes nerve pain known as diabetic peripheral neuropathy. The FDA approved Cymbalta for treatment of diabetes neuropathy but does Cymbalta’s pros outweigh it’s cons?

Cymbalta is a dual re-uptake inhibitor of serotonin and norepinephrine. It is this characteristic that causes Cymbalta to drastically reduce pain. I have been checking out some message boards in which people who began taking Cymbalta saw a great improvement in their pain associated with diabetic peripheral neuropathy. If you’ve never had nerve pain, you just can’t imagine how painful it is. Pretty much nothing gives you relief. That is why Cymbalta is becoming so popular to treat the pain.

Not only does Cymbalta relieve some of the nerve pain associated with the diabetic peripheral neuropathy but since it is an antidepressant it is also providing a better quality of life to those suffering from both pain and depression. The risk of depression is raised in diabetes patients.



Think your diabetes is difficult to manage? Meet Calvin. A 10 year old boy with a deep enthusiasm for life. But every day is a constant battle against an enemy that will not relent; an enemy that requires careful vigilance and treatment; an enemy that science can not‚ as yet‚defeat.

After reading up on the subject of Cymbalta for diabetes peripheral neuropathy I started coming across a lot of message boards containing messages from diabetes patients who were in the process of weening off of Cymbalta because it was no longer working for their pain. Why were they needing to ween off of Cymbalta? Because the Cymbalta withdrawal is pretty severe. So severe, that even though people are slowly weening off (I’m talking taking a couple of months to ween off) they are still experiencing severe withdrawal symptoms.

I have found a site that lists a possible 85 Cymbalta withdrawal symptoms. Some of these are minor and just irritating such as canker sours but otherwithdrawal symptoms can be quite sever and disruptive to daily life such as a buzzing in one’s brain. I have seen those called brain zaps or brain shivers. Try walking around with what feels like electric shocks in your brain and see how normal you appear.

So to me, it seems like in some cases the Cymbalta works for diabetes peripheral neuropathy for a couple of months but then it takes up to 3 more months after realizing it doesn’t work anymore to actually be completely off of the Cymbalta. Is it worth it? That is really up to the person that is going to be taking it. I understand that diabetes nerve pain can be almost intolerable so I can see why someone would want to try anything that might possibly work.

The information provided on battlediabetes.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of battlediabetes.com nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
http://www.battlediabetes.com/cymbalta-diabetes-nerve-pain


Thursday, June 22, 2017

Cobra Venom May Help Neuropathic Pain


Today's interesting post from rafflesmuseum.wordpress.com (see link below) talks about using snake venom to control neurological pain. It comes from Singapore and is another story about the potential for various venoms to be modified to block pain signals. In the past we've heard about scorpions and other creatures with venom in their arsenal being potential pain blockers but this one shows signs of some real progress. There is a possibility that a product could be on the market by 2016/17. If such a product can take the place of morphine and other opioids, it will show real progress in the search for effective pain control.




Powerful painkiller from cobra venom

Posted on 15 February 2013 by jangancemas


NUS researchers develop painkiller 20 times stronger than morphine – David Ee

JUST one bite from a king cobra kills a fully grown man in hours.

But the snake’s lethal venom could one day kill pain in humans instead.

Researchers at the National University of Singapore have made a powerful painkiller from it – 20 times more potent than morphine.

Its strength means it could be particularly effective for dealing with neuropathic pain, which is often caused by nerve damage and can be difficult to treat.

Crucially, said the team, laboratory tests have so far shown that it causes no side effects, even at 2,000 times the effective dose.

This is unlike other painkillers in use today, said lead researcher Kini Manjunatha. For instance, using morphine can cause problems ranging from constipation to addiction.

Even common painkillers such as aspirin can cause gastric pains.

The new drug is expected to be tested in clinical trials here from next year, with the aim of marketing it by 2016 or 2017.

Professor Kini – whose fascination with snakes began as a child back in India, where he heard of villagers dying from their bites – explained the paradoxical allure of the reptiles’ venom.

“Proteins in snake venom are very similar in structure to human proteins, yet ours are not toxic.”

Snake bites may kill up to 100,000 people each year, he said, yet all forms of their venom potentially have life-saving properties.

Captopril, a drug used to treat high blood pressure, was developed using the poison from vipers.

And British scientists have discovered that snake venom can transform back into harmless molecules.

This could pave the way for the development of new drugs to treat diseases such as cancer and diabetes.

The Singapore university’s research started in 2003 and has cost $3 million to date, funded internally and by the Agency for Science, Technology and Research.

Prof Kini and his team painstakingly screened king cobra venom imported from commercial snake farms in the region until they identified the lone venom protein with painkilling properties.

They then isolated the specific portion of the protein involved in the process. Not doing so may mean it remains toxic.

Their research found king cobra venom could also help treat high blood pressure and dangerous blood clots.

“We know perhaps only 1 per cent of the benefits of snake venom,” said Prof Kini. “It’s a very exciting challenge.”

Remarking on the Chinese Year of the Snake, he said: “It’s nice that the animal I’ve been fascinated with all my life gets the spotlight once every 12 years.”

(c) 2013 Singapore Press Holdings Limited

http://rafflesmuseum.wordpress.com/2013/02/15/powerful-painkiller-from-cobra-venom/

Wednesday, June 14, 2017

Eighty Six Year Old Inventor Invents Solution For Neuropathic Pain


Today's post from washingtonpost.com (see link below) is a long one but what a great one to read! Not only is this guy's invention a serious breakthrough in the treatment of neuropathic pain but the story behind it is truly inspiring. If you don't read anything else this week, read this one - it'll brighten up your day!

The genius inventor who says he’ll eliminate chronic pain with a simple device

By Terrence McCoy July 27 at 6:00 AM 

 

Robert Fischell is Maryland’s greatest inventor. (Photo by Toni L. Sandys/ The Washington Post)

At exactly 1:45 p.m. on a Tuesday, one of the nation’s most prolific inventors arrives at an International House of Pancakes via sports car. It gleams quicksilver in the afternoon sun. “They call this a Jaguar,” purrs Robert Fischell, who’s credited with saving tens of thousands of lives and ushering in the modern era of satellite navigation. “I think it’s named after a cat.”

Then Fischell, in a collared shirt unbuttoned low, puts the Jag into action, weaving it through traffic on his way toward the University of Maryland. He has a meeting there at 2 p.m., and it looks to be an important one. The tech guys are rolling out his newest invention. And this one — a contraption he says could cure chronic pain — should be a doozy.

The life of Robert Fischell has been one of doozies. A space scientist turned inventor, Fischell has authored more than 200 patents that range from the grave to the quirky. He has invented a rechargeable pacemaker, an implantable cardiac defibrillator, a device that warns of epileptic seizures, an insertable insulin pump and a gizmo that zaps migraines before they start. He has also fashioned a bevy of penile prosthetics to cure erectile dysfunction as well as something called a “bowl for keeping cereal crispy.”

But this invention, he says, is his most ambitious yet. “Chronic pain costs the American people $600 billion every year,” Fischell says in a lilting staccato flecked with traces of his Bronx youth. “Six. Hundred. Billion. Dollars.”

Still, Fischell is not a young man. He’s 86. He’s had two surgeries for cataracts in the last six weeks. He has an artificial left knee.

Fischell, who grimaces when mortality arises in conversation, knows more days are behind him than ahead. So he keeps a frenetic pace. He clocks 10-hour days at his office. He drives his Jaguar fast. He drinks unsweetened tea by the quart. This could be his last great invention. He has to finish it soon.

It’s now 1:55 p.m. Fischell slams the Jaguar into a parking space. He hustles into the Fischell Institute for Biomedical Devices, arriving at a conference room. Fischell looks around. It’s empty. He’s early.

The language of pain


The first scientist to join him is Lex Schultheis — a man who’s ready to talk pain. Schultheis wears camouflage moccasins and an arm sling and has ruffled white hair. Some weeks back, Schultheis said, he took a bad spill while astride his unicycle and “fractured my arm into a hundred pieces.” It hurt like something else. But that, he said, was a good thing.

“There are two kinds of pain,” said Schultheis, the director of the university’s innovation initiative. “Good pain and bad pain. There’s the pain that prevents you from reinjuring yourself,” which he experienced after his unicycle accident. But then there’s “bad pain,” he said. “It’s when the repair is done and the doctors have done everything they can. It’s not serving a purpose.”

One-third of Americans know what Schultheis is talking about. We live in an era of chronic pain. It batters more people than diabetes, heart disease and cancer — combined. The answer thus far has been painkillers, and the number of opioid prescriptions have tripled in the last 15 years, according to the CDC. This, however, has been a deal with the devil. Between 1999 and 2010, the number of opioid overdoses surged from 4,000 to 16,500 amid mounting evidence suggesting that painkillers actually increase pain sensitivity.

That got Fischell thinking. What if drugs aren’t the answer? What if they communicate with nerves in the wrong language? What if it’s time for a new language?

If the body is a house, the nervous system is its electrical wiring. The network, which has millions of entry points throughout the body, communicates in electrical pulses. A finger prick shoots a series through a long axon to the spine — the pathway that all pain signals must pass — until they strike the brain. The higher the frequency of the nerve’s signal to the brain, the greater the pain.

So Fischell, now holding forth at his meeting, said the best way to calm down those nerves is to speak to them in a language they understand — electricity. The problem, of course, is that electricity kills. Wouldn’t it do more damage than good? Fischell laughed at the question like he was in on a secret joke. The answer, he said, was just around the corner.

A barrel-chested engineer named Wes Lawson materialized at the doorway. Fifteen minutes late, he wheeled in a large metallic box of blinking lights and dials. A long cord affixed to a copper coil dangled from its side.

This was Fischell’s latest invention. This device, he said, interrupts a pain neuron’s electrical signal before it reaches the brain. And the best part, Fischell said, is that it doesn’t use electricity at all. It uses magnetism.

‘A major step forward’

If there’s a moment that marked the genesis of this device, it came 15 years ago in the mountains of New York. There, ensconced inside at the Mohonk Mountain House, sat Robert Fischell with his son, a physicist, and a neurologist named Adrian Upton. They called their meeting an “innovation retreat.”

“I don’t know why it is, but the three of us could always get together and invent stuff,” said David Fischell, who holds 85 patents and helms several biomedical companies that have commercialized the family’s inventions. “So we went to this quiet spot and we literally spent five or six hours a day for two days talking about different areas where electric stimulation could help.”

No one can remember the details of who said what. But at some point, one of the three inventors brought up migraines. The brain, they reasoned, was a natural place to use electricity. “If pacemakers and electricity works for the heart, then it should work for the brain considering it’s much more electrical than the heart,” David Fischell said. But the trick was to get the electricity to the brain. So they mulled a concept in physics known as Faraday’s law of induction. The principle, which also gave rise to electromagnetic generators, holds that a pulse of magnetic energy will induce an electrical current. And that, they thought, might grant them a way into the brain.

Diagnostic researchers had already used this technology — called transcranial magnetic stimulation — to poke and prod the brain with bursts of electricity. But no one, David Fischell said, had used it to treat the brain.

So Upton, back at his office in Ontario at McMaster University, fired a pulse of magnetic energy into the skull of a patient who complained of migraine pain and an aura. The patient’s aura then shifted shape and size. This suggested something big: Electricity could affect the neurons behind the migraine. “The overall principle is very straight forward,” Upton said. “Migraines are like epilepsy in that there is an electrical spreading in the brain, and if you can interrupt that spreading, you could stop the migraine.”

In 2000, the three inventors filed an application for a patent. It detailed a portable device that presses against the skull and shoots magnetic energy into the brain, expunging a migraine before it starts. One study published in Neurology called such technology a “major step forward” in chronic migraine treatment. Another study in Neurological Research found that 50 out of 51 migraine patients reported a 50 percent reduction in headache frequency after one week of treatment. The Journal of Neurological Sciences said it “ameliorates chronic migraine” in one part of the brain.

Still, 13 years passed before the Food and Drug Administration approved Fischell’s device. In those 13 years, a lot of life happened. Fischell started a department of biomedical engineering at the University of Maryland. He criticized the FDA at a Congressional hearing for what he called its sluggish pace in approving patents for consumer use. And his wife of 54 years died of leukemia.

It crushed Fischell. For a man who has hung a sign that says “nothing is impossible” in his office, he couldn’t accept his own helplessness. “I couldn’t save her,” said Fischell, who watched his wife’s deterioration in daily doctor visits. “I’m an inventor. I invent things. But I couldn’t come up with anything that could save her.”

A little more than a year after her death, Fischell married his former secretary, which surprised his three children. “It seemed a little fast,” son Tim Fischell said. “But he is not someone who does well alone. He is not someone who would be OK alone, but he and his [new wife, Susan] had known each other and now are very devoted.”

And it was this relationship that inspired Fischell’s greatest pursuit yet: his quest, at 84, to eliminate chronic pain.



The migraine headache device invented by Robert Fischell. (Photo by Toni L. Sandys/ The Washington Post)

‘Inventing is a blessing and a curse’

Fischell lives inside a cavernous ranch-style home tucked among trees on an estate he calls “Willow Oaks.” He rarely leaves it. He holds meetings there when he can. He takes meals at the nearby Crossroads Pub. He hangs out with neighbors. One such gathering came in December of 2013 when one neighbor, a woman in her seventies, was dying of cancer.

“She’s telling my wife how severe the pain is in her feet from two years of chemotherapy,” Fischell said. “There are 10 million Americans with severe foot pain. And my Suzie, who doesn’t even have a college degree said, ‘Well, why don’t we use Bob’s migraine device to erase your foot pain?’ And I said, ‘What the hell are you talking about?’ A migraine is a migraine. This is foot pain.” But the suggestion nonetheless stayed with him. Possibilities sloshed around in his mind that whole night. He wondered: Could the same principles that govern the migraine invention do the same for chronic pain?

Fresh research suggesting receptors in the meninges produce migraines has emboldened Fischell’s hypothesis. If electrical currents can disrupt pain receptors in the meninges, it might do the same for other parts of the body. So Fischell has spent weeks drawing. He has drawn a boot-shaped contraption that someone can slide their foot into to receive a jolt of electromagnetic energy. He has drawn a shoulder harness that targets the rotator cuff. He has drawn a belt festooned with a giant copper coil that someone with back pain can wear. He gave his technicians weeks to forge 10 prototypes that he can use in a clinical trial beginning in September to test his hypothesis.

Everything’s moving fast — but is it too fast? Fischell’s career, after all, was forged in space laboratories at a time when astronauts were shooting off to the moon and everything seemed possible. That optimism has informed his decisions in innovation. And while it has driven him farther than most, it has also misguided him at times. (It’s unclear, for instance, who will need a cereal bowl that ensures crispy corn flakes.)

“Folks who don’t know him that well may be suspicious of his optimism,” Schultheis said. “He’ll tell you that this will cure all pain. And while he’s not unrealistic, there are projects that he works on that aren’t successful.”

Fellow inventor Upton agrees: “This isn’t something that’s going to happen over night as some sort of miracle. That’s not realistic. But there’s no question that the type of stimulators he’s working on now help pain, no question.”

But Fischell’s not interested in talking about things that can’t happen. He’s not interested in discussing his age, or his mortality. He’s not interested in considering what he’ll do when the work stops.

As he departs his meeting on a recent Tuesday and climbs into his Jaguar, he says he’s interested in getting back home to his office. There’s so much work to do. There’s no time to waste.

“Inventing is a blessing and a curse,” he said. “But it’s fun, too. It’s a game. But the stakes of this game couldn’t be graver.”

http://www.washingtonpost.com/news/inspired-life/wp/2015/07/27/the-genius-inventor-who-says-hell-eliminate-chronic-pain-with-a-simple-device/

Sunday, May 21, 2017

Capsaicin For Neuropathic Pain An Update


Today's post from informahealthcare.com (see link below) is a short summary of the findings of a German research study into the effectiveness of high-strength capsaicin patches in reducing neuropathic pain (Qutenza is the most commonly used). Capsaicin cream and patches have sort of fallen off the radar in the last two years but remain an alternative treatment for neuropathic pain. Their reduced popularity may well be due to the difficulty of application and the care needed to avoid burning. The base component capsaicin comes from chili peppers and is extremely powerful, especially in the concentration used on the patches. You really do need expert guidance as to how to apply them and what to do if the negative symptoms are too strong. That said, studies consistently show that capsaicin high strength patches do work in reducing nerve pain. If you've not thought about them, it may be worth discussing the option with your doctor.




High concentration capsaicin for treatment of peripheral neuropathic pain:

...effect on somatosensory symptoms and identification of treatment responders
April 2014, Vol. 30, No. 4 , Pages 565-574 (doi:10.1185/03007995.2013.869491)

Johanna Höpera, * Stephanie Helferta, * Marie-Luise S. Heskampb, Christian G. Maihöfnerc, Ralf Barona
aDivision of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein,
Kiel, Germany
bMedical Department, Astellas Pharma GmbH,
Munich, Germany
cDepartment of Neurology, Fürth Hospital,
Fürth, Germany
Address for correspondence:
Prof. Dr. med. Ralf Baron, Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein,
Campus Kiel, Arnold-Heller-Str. 3, Haus 41, 24105 Kiel, Germany. Tel: +49 431 597 8504; Fax: +49 431 597 8530; r.baron@neurologie.uni-kiel.de

*These two authors contributed equally to the paper.

Background:

Pain is usually assessed by spontaneous pain ratings. Time-dependent (brief attacks) or evoked (allodynia) phenomena, common in neuropathic pain, are not captured. To evaluate the overall effectiveness of a treatment, improvement of all sensory symptoms should be measured. Since the pattern of sensory abnormalities might hint at the underlying mechanisms of pain, this baseline information may aid in predicting the treatment effect. Data on sensory neuropathic abnormalities (painDETECT questionnaire) were analyzed aiming to (1) evaluate the frequency of neuropathic symptoms in different peripheral neuropathic pain syndromes, (2) assess the effect of capsaicin 8% patch on neuropathic symptoms and (3) identify treatment responders based on baseline values.

Methods:

Data analysis of a prospective 12 week non-interventional trial in peripheral neuropathic pain treated with capsaicin 8% cutaneous patch. Average pain intensity during the past 24 hours, pain descriptors and qualities of neuropathic pain were assessed to characterize the patients’ sensory symptoms at baseline and to document changes.

Results:
(1) Characteristic symptoms of neuropathic pain were present in all peripheral neuropathic pain syndromes, but frequencies varied in the individual syndromes. (2) Topical capsaicin 8% treatment significantly reduced the overall pain intensity and resulted in a reduction of sensory abnormalities. (3) Short disease duration predicted a better treatment effect. High painDETECT scores, the presence of burning and pressure-evoked pain were weakly associated with treatment response.

Conclusions:
Topical capsaicin 8% treatment effectively reduced sensory abnormalities in peripheral neuropathic pain. The association of sensory symptoms and treatment response aids in understanding the mechanism of action of high concentration capsaicin. It is, however, not possible to use sensory symptom patterns to predict treatment response to capsaicin on an individual level.

Limitations:

Completion of painDETECT was optional and therefore data was not available for all patients. Further studies for confirmation of these results are needed.

http://informahealthcare.com/doi/abs/10.1185/03007995.2013.869491

Sunday, May 14, 2017

Is Lamotrigine Any Use For Neuropathic Pain


Today's post from onlinelibrary.wiley.com (see link below) talks about Lamotrigine (Lamictal in Europe) as a treatment for neuropathic pain. Lamotrigine is another anti-epilepsy drug used to combat nerve pain and is becoming more and more popular as doctors run out of options for patients with stubborn symptoms. However, this study is pretty damning in its conclusions and views Lamotrigine as being no better than a placebo. This puts the patient in a difficult position, as the doctor  or specialist has prescribed it, often based on so-called 'other patient experiences'. However, drug company representatives are often the driving force behind its prescription and you need to really talk it over with your doctor before accepting it as a treatment. Using research conclusions such as this one may strengthen your argument. After that, you have to make a decision as to whether to take it or not and run the risk of your doctor feeling offended that you're rejecting his or her suggestions. However, it's your health at issue here and you deserve the best treatment. The potential side effects are also an issue to think about. May be worth asking for an alternative.

Lamotrigine for chronic neuropathic pain and fibromyalgia in adults

Philip J Wiffen*,
Sheena Derry,
R Andrew Moore


Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 3 DEC 2013

Assessed as up-to-date: 26 NOV 2013

DOI: 10.1002/14651858.CD006044.pub4

Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Abstract

Background


This is an update of the original Cochrane review entitled Lamotrigine for acute and chronic pain published in Issue 2, 2007, and updated in Issue 2, 2011. Some antiepileptic medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This updated review adds no new additional studies looking at evidence for lamotrigine as an effective treatment for chronic neuropathic pain or fibromyalgia. The update uses higher standards of evidence than previously.

Objectives

To assess the analgesic efficacy of lamotrigine in the treatment of chronic neuropathic pain and fibromyalgia, and to evaluate adverse effects reported in the studies.

Search methods

We identified randomised controlled trials (RCTs) of lamotrigine for chronic neuropathic pain and fibromyalgia (including cancer pain) from MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL). We ran searches for the original review in 2006, in 2011 for the first update, and subsequent searches in August 2013 for this update. We sought additional studies from the reference lists of the retrieved papers. The original review and first update included acute pain, but no acute pain studies were identified.

Selection criteria


RCTs investigating the use of lamotrigine (any dose, by any route, and for any study duration) for the treatment of chronic neuropathic pain or fibromyalgia. Assessment of pain intensity or pain relief, or both, using validated scales. Participants were adults aged 18 and over. We included only full journal publication articles.

Data collection and analysis

Two review authors independently extracted efficacy and adverse event data, and examined issues of study quality. We performed analysis using three tiers of evidence. The first tier used data where studies reported the outcome of at least 50% pain reduction from baseline, lasted at least eight weeks, had a parallel group design, included 200 or more participants in the comparison, and reported an intention-to-treat analysis. First-tier studies did not use last observation carried forward (LOCF) or other imputational methods for dropouts. The second tier used data that failed to meet this standard and second-tier results were therefore subject to potential bias.

Main results


Twelve included studies in 11 publications (1511 participants), all with chronic neuropathic pain: central post-stroke pain (1), chemotherapy-induced neuropathic pain (1), diabetic neuropathy (4), HIV-related neuropathy (2), mixed neuropathic pain (2), spinal cord injury-related pain (1), and trigeminal neuralgia (1). We did not identify any additional studies. Participants were aged between 26 and 77 years. Study duration was two weeks in one study and at least six weeks in the remainder; eight were of eight-week duration or longer.

No study provided first-tier evidence for an efficacy outcome. There was no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of 200 mg to 400 mg daily. Almost 10% of participants taking lamotrigine reported a skin rash.

Authors' conclusions


Large, high-quality, long-duration studies reporting clinically useful levels of pain relief for individual participants provided no convincing evidence that lamotrigine is effective in treating neuropathic pain and fibromyalgia at doses of about 200 to 400 mg daily. Given the availability of more effective treatments including antiepileptics and antidepressant medicines, lamotrigine does not have a significant place in therapy based on the available evidence. The adverse effect profile of lamotrigine is also of concern.

Plain language summary


Lamotrigine (an antiepileptic drug) for chronic neuropathic pain or fibromyalgia

Neuropathic pain is pain coming from damaged nerves. It is different from pain messages carried along healthy nerves from damaged tissue (a fall, or cut, or arthritic knee). Neuropathic pain is treated by different medicines than pain from damaged tissue. Medicines like paracetamol or ibuprofen are not effective in neuropathic pain, while medicines that are sometimes used to treat depression or epilepsy can be very effective in some people with neuropathic pain. Our understanding of fibromyalgia (a condition of persistent, widespread pain and tenderness, sleep problems, and fatigue) is lacking, but fibromyalgia can respond to the same medicines as neuropathic pain.

Lamotrigine is a medicine used to treat epilepsy, and so might be a useful medicine for neuropathic pain or fibromyalgia.

On 26 November 2013 we performed searches to look for clinical trials where lamotrigine was used to treat neuropathic pain or fibromyalgia. We found 12 studies of reasonable quality that tested lamotrigine against placebo for a number of weeks. Almost half of the 1511 people in the studies had painful limbs because of damaged nerves caused by diabetes, and seven different painful neuropathic conditions were examined. No studies looked at fibromyalgia.

Lamotrigine did not help the pain, and was no different from placebo except in causing more side effects. Adverse events were more frequent with lamotrigine than placebo, with rash in 1 person in 27.

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006044.pub4/abstract

Friday, May 12, 2017

Why Cannabis Must Be At Least An Option For Neuropathic Pain


Today's post from whaxy.com (see link below) returns to a common theme on this blog and that is the potential cannabis has for relieving nerve pain. It's not that we are for or against cannabis, it's just that cannabis remains one of the very few proven treatments for dulling nerve pain and for that reason, deserves the best research and trustworthy conclusions. Not only that but the moral (but non-scientific) objections to cannabis form a considerable barrier to making progress with its development as a truly useful analgesic for neuropathy sufferers. This article is easy to follow and gives a breakdown of what it is, how it works and why it's so effective. Definitely worth a read.
 
Study Reveals Cannabis Significantly Reduces Neuropathic Pain
By Marie Veksler February 14, 2015 

A study published in the The Journal of Pain: Official Journal of the American Pain Society found that low-doses of vaporized cannabis provide significant improvement for neuropathic pain sufferers. The study, a double-blind crossover, was placebo-controlled, and tested the efficacy of cannabis to treat the neuropathic pain of patients who were not responding to traditional treatments.

In the study, patients with central and peripheral neuropathic pain were administered either a medium-dose of 3.53 percent, a low-dose of 1.29 percent, or a placebo through vaporizing. Each patients’ pain was then rated using a visual analog scale of intensity. Psychoactive side effects and brain function were also monitored and evaluated throughout the study.

Analyzed results revealed that the cannabis provided at least the equivalent pain reduction as other patients reported from using traditional neuropathic pain medication. The low-dose (1.29%) and medium-dose (3.53%) were equally as effective, proving that even the lower dose of cannabis improved symptoms.

As a result, the study revealed that “even at low doses, [cannabis] may present an effective option for patients with treatment-resistant neuropathic pain.” The study conclusion also stated that “one might not anticipate a significant impact on daily functioning.”


What is neuropathic pain?

Neuropathic pain is the result of nerve damage to the peripheral nervous system, which includes all nerves outside of the brain and spinal cord. It is usually described by patients as chronic. The damaged nerves send incorrect signals to the body that there is pain. The damage to nerve fibers is most often the result of a tissue injury caused by trauma or infection. Patients describe this kind of pain as “shooting and burning” or “tingling and numbness.”
What causes neuropathic pain?

The one, specific cause of neuropathic pain is often unknown unless it is the result of amputation (phantom limb syndrome). However, people diagnosed as suffering from neuropathic pain often also had or have one or more of the following:


Diabetes
Alcoholism
Back, leg, and hip problems
Chemotherapy
Facial nerve problems
HIV infection or AIDS
Multiple sclerosis
Shingles
Spine surgery 


Why is cannabis effective as a neuropathic pain reliever?


Cannabis is made up of many, diverse chemical compounds known as cannabinoids. There are more than 60 cannabinoids found in marijuana that we know to exist, and each of them reacts differently in the human body and produces different responses. Cannabinoids are responsible for producing all of the effects experienced when using cannabis.

Unfortunately, we know very little about most of them because researchers have difficulty gaining access to cannabis to study because of it’s current listing as a Schedule I substance under the Controlled Substances Act of 1970. Being listed as a Schedule I, deemed the worst of the five categories, means that it has “no accepted medical value in the United States.” Because of this, researchers are rarely granted federal permission to study it.

Scientists have been able to identify the most common medicinal benefits produced by only seven different cannabinoids. Four of those seven are known to be analgesic, or pain relieving. The four known to act as strong pain relievers are:


Tetrahydrocannabinol (THC)
Cannabidiol (CBD)
Cannabichromene (CBC)
Cannabinol (CBN)

Another reason that many patients report having a preference to medical marijuana is because the side-effects produced by cannabis, including those that are psychoactive, are less debilitating than those produced by many of the strong opiod pain reliving pharmaceuticals like Oxycontin.

Such heavy-hitting pharmaceuticals make it difficult for patients to function during normal day-to-day activities, and can cause serious addiction or result in accidental overdoses and deaths. A cannabis overdose has never resulted in the death of a person. A recent report even revealed that opiod overdoses were reduced by 25 percent in states where medical marijuana is legal because patients in those states were more likely to use cannabis.

Although much more research needs to be completed on this topic to make any certain conclusions, there is at least enough evidence to prove that cannabis as a viable treatment option for neuropathic pain should be explored further.

https://www.whaxy.com/learn/marijuana-treatment-neuropathic-pain

Lpathomab A Future Drug For Neuropathic Pain


Today's post from cnbc.com (see link below) is a tually a press-release and therefore an advertisement for a new treatment for neuropathy which has been submitted to the FDA for approval. Normally, this blog doesn't advertise in any form but when a new drug seems to be promising and will engender interest among neuropathy patients, it has to be noted. The drug, Lpathomab, "is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain." This may mean little to the casual reader but is indicative of the depth of study now being put into neuropathic pain treatments. It is becoming clear that studies at molecular level are becoming more sophisticated and showing real promise of real solutions in the future. Whether Lpathomab turns out to be successful or not, is the question and it has to be said that the company are pretty much at the beginning of the process leading to a drug on the shelves. They need FDA approval to continue their development plans but although it may be difficult to pronounce, keep Lpathomab in the back of your mind as being a possibility for the future.

 Lpath Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain
  Monday, 2 Feb 2015 | 8:00 AM ETPR Newswire
 

SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), a leader in the discovery and development of lipid-targeted therapeutics, announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards.

Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.

"We've made great progress in advancing Lpathomab towards the clinic and are eager to start our first-in-human study for our third antibody product candidate produced using our ImmuneY2TM drug discovery engine," said Dario Paggiarino, M.D., chief development officer of Lpath. "We believe our approach of targeting the ligand (LPA) with an antibody may have distinct mechanistic advantages over traditional small molecule approaches to address an area of significant unmet medical need."

About Lpath

San Diego-based Lpath, Inc. (NASDAQ: LPTN) is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, for neuropathic pain and an anti-leukotriene antibody, Altepan, which is being studied in models of inflammatory bowel disease, respiratory disease and inflammation. For more information, visit www.Lpath.com.

Forward-Looking Statements

 
Lpath cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Lpath's business, including, without limitation: Lpath may not be permitted by the FDA to proceed with the Phase 1 clinical trial of Lpathomab on a timely basis, without first being required to conduct additional studies, or at all; the final results of Lpath's preclinical studies and clinical trials may be different from Lpath's studies or interim data results and may not support further clinical development and/or the commercialization of its drug candidates; Lpath may not successfully complete its existing and any additional clinical trials for its drug candidates on a timely basis, or at all; Lpath may fail to obtain required governmental approvals for any of its drug candidates; Lpath may not be successful in maintaining its commercial relationship with Pfizer Inc. or any third party that may acquire the exclusive option Lpath granted to Pfizer for iSONEP; and Lpath may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the risk factors and uncertainties that may affect the realization of forward-looking statements is set forth in Lpath's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Such documents may be read free of charge on the SEC's website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which are effective only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Lpath undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

COMPANY CONTACT:
Gary Atkinson
Chief Financial Officer
Lpath, Inc.
858-926-3202
gatkinson@lpath.com

PUBLIC RELATIONS CONTACT:
Canale Communications
Rachel Hutman
619-849-5384
rachel@canalecomm.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lpath-submits-investigational-new-drug-application-for-lpathomab-for-neuropathic-pain-300028833.html

SOURCE Lpath, Inc.

http://www.cnbc.com/id/102388470#.

Thursday, May 4, 2017

Can Skin Signals Cause Neuropathic Pain


Not the easiest article to understand but one that gives a fascinating alternative to the idea that neuropathic pain is caused by damaged nerves. It comes from esciencenews.com (see link below) and suggests that the pain signals are produced by the skin itself. The science is fairly complex but further Googling will provide further information. This one may surprise your neurologist when you next visit him or her.

Researchers discover potential cause of chronic painful skin
Published: Wednesday, June 8, 2011

A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.

A Medical Mystery
For years, researchers have known that increased amounts of a molecule called Calcitonin Gene-Related Peptide (CGRP) is found in the skin of chronic pain patients. The source of the increased CGRP was thought to be certain types of sensory nerve fibers in the skin that normally make and release a type or "isoform" called CGRP-alpha. Curiously, however, the authors of the current study found that nerve fibers containing CGRP-alpha are actually reduced under painful conditions – leading them to investigate where the increased CGRP in the skin came from.

The answer, surprisingly, was that the skin cells themselves generate increased amounts of a lesser-known "beta" isoform of CGRP. This skin cell-derived CGRP-beta is increased in painful conditions and may be sending pain signals to remaining sensory nerve fibers in the skin. The discovery of CGRP-beta as a therapeutic target presents a potentially important new treatment approach.

"Since CGRP-alpha normally plays an important role in both the regulation of blood flow and normal inflammatory responses, targeting this molecule as a treatment for chronic pain could cause undesired side-effects on circulation," said the paper's corresponding author, Phillip J. Albrecht, Ph.D., Assistant Professor of Neuroscience at Albany Medical College and Vice President at Integrated Tissue Dynamics, LLC, whose team conducted the research. "However, since we know that these two forms of CGRP are derived from separate genes, we may be able to selectively manipulate the beta isoform without affecting the alpha, and dramatically reduce unwanted toxicities -- a common problem limiting the successful development of novel pain therapeutics. This is really a two-for-one discovery: a novel mechanism we can specifically target in a novel skin location."

The discovery that CGRP-beta from keratinocyte cells of skin may be causing pain has profound implications for the treatment and study of a host of chronic neuropathic pain conditions such as shingles, diabetic neuropathy, and physical injury, which altogether affect approximately 30 million people in the U.S. who collectively spend more than $4.5 billion each year to treat chronic nerve pain.

A New Translational Research Platform

The present study was a comprehensive translational research project that integrated results from cell culture, animal models of chronic pain and human pain condition tissues to confirm that CRGP is generated in keratinocytes in each of those systems. The study also demonstrates how a translational research platform can be utilized to discover novel targets and provide drug companies with better predictive data that can be used to make time- and cost-reducing decisions early in the drug discovery process.

To observe differences between CGRP in healthy and inflamed or painful skin, the researchers used an imaging methodology called chemomorphometric analysis (CMA), a technique they use to observe, quantify, and characterize molecules like CGRP in the microscopic structure of skin samples half the size of a pencil eraser. A commercially expanded version of the technique, pioneered by Integrated Tissue Dynamics, LLC, interpreted those results and integrated them with assessments of the genetic activity for each CGRP isoform, which led to the discovery that the beta molecule, not the alpha, predominated in keratinocytes.

"We are especially excited by our translational research results because the identification of beta CGRP in keratinocytes will have immediate value in the clinical setting, and also demonstrates how our CMA technology can deliver on the promise of translational medicine," said Frank L. Rice, Ph.D., Professor of Neuroscience at Albany Medical College and CEO at Integrated Tissue Dynamics, LLC. "Furthermore, the identification of beta CGRP in skin keratinocytes may become a useful independent biomarker for the therapeutic effectiveness of chronic neuropathic pain treatments."

The initial discovery stems from the Ph.D. dissertation research of Albany Medical College graduate student Quanzhi Hou, M.D., who is being co-mentored by Drs. Albrecht and Rice, in conjunction with research by Travis Barr, Ph.D., a former graduate student in the lab. Dr. Hou's research was made possible with the support of an international network of researchers and clinicians from Albany Medical College, the Feinberg School of Medicine of Northwestern University, Boston College, the University at Albany, the University of Brescia (Italy), the Israel Institute of Technology, and companies Vertex Pharmaceuticals and Integrated Tissue Dynamics. Dr. Rice noted that "As a co-discovery in the labs of Albany Medical College and Integrated Tissue Dynamics, we are filing a patent to develop our research and commercialization options."

About the Study

The present study found CGRP levels increased in keratinocytes of painful skin from humans with postherpetic neuralgia (PHN) and complex regional pain syndrome type 1 (CRPS). Elevated CGRP levels were also found in skin keratinocytes from monkeys infected with the equivalent of HIV, and in rats with nerve injury and inflammatory pain conditions similar to those caused by accidents and shingles. CGRP was also found in human keratinocyte cell cultures, and the beta isoform predominated.

Previous research has documented abnormally increased levels of CGRP in the skin, blood, and cerebral spinal fluid under a variety of human and animal chronic pain conditions, and CGRP has consequently become a leading target for chronic pain therapeutics. However, prior research has largely not distinguished between the two isoforms and it has been assumed that the increased CGRP seen in previous studies was the alpha isoform generated by nerves that supply sensory innervation to the skin.

Recently, members of the Intidyn and the Medical College group also published a pioneering study demonstrating that CGRP (likely alpha) innervation to the blood vessels plays a previously unknown role in normal skin sensation. The current findings now add to that story, the role of a second (beta) isoform produced in a unique location (keratinocytes) - which likely also plays a critical role in both normal sensation and chronic painful conditions.

http://esciencenews.com/articles/2011/06/08/researchers.discover.potential.cause.chronic.painful.skin